Upregulation of transmembrane endothelial junction proteins in human cerebral cavernous malformations by Burkhardt, J K et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2010
Upregulation of transmembrane endothelial junction proteins in
human cerebral cavernous malformations
Burkhardt, J K; Schmidt, D; Schoenauer, R; Brokopp, C; Agarkova, I; Bozinov, O;
Bertalanffy, H; Hoerstrup, S P
Burkhardt, J K; Schmidt, D; Schoenauer, R; Brokopp, C; Agarkova, I; Bozinov, O; Bertalanffy, H; Hoerstrup, S P
(2010). Upregulation of transmembrane endothelial junction proteins in human cerebral cavernous malformations.
Neurosurgical Focus, 29(3):E3.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Neurosurgical Focus 2010, 29(3):E3.
Burkhardt, J K; Schmidt, D; Schoenauer, R; Brokopp, C; Agarkova, I; Bozinov, O; Bertalanffy, H; Hoerstrup, S P
(2010). Upregulation of transmembrane endothelial junction proteins in human cerebral cavernous malformations.
Neurosurgical Focus, 29(3):E3.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Neurosurgical Focus 2010, 29(3):E3.
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human cerebral cavernous malformations
Abstract
OBJECT: Cerebral cavernous malformations (CCMs) are among the most prevalent cerebrovascular
malformations, and endothelial cells seem to play a major role in the disease. However, the underlying
mechanisms, including endothelial intercellular communication, have not yet been fully elucidated. In
this article, the authors focus on the endothelial junction proteins CD31, VE-cadherin, and occludin as
important factors for functional cell-cell contacts known as vascular adhesion molecules and adherence
and tight junctions. METHODS: Thirteen human CCM specimens and 6 control tissue specimens were
cryopreserved and examined for the presence of VE-cadherin, occludin, and CD31 by
immunofluorescence staining. Protein quantification was performed by triplicate measurements using
western blot analysis. RESULTS: Immunofluorescent analyses of the CCM sections revealed a
discontinuous pattern of dilated microvessels and capillaries as well as increased expression of occludin,
VE-cadherin, and CD31 in the intima and in the enclosed parenchymal tissue compared with controls.
Protein quantification confirmed these findings by showing upregulation of the levels of these proteins
up to 2-6 times. CONCLUSIONS: A protocol enabling the molecular and morphological examination of
the intercellular contact proteins in human CCM was validated. The abnormal and discontinuous pattern
in these endothelial cell-contact proteins compared with control tissue explains the loose intercellular
junctions that are considered to be one of the causes of CCM-associated bleeding or transendothelial
oozing of erythrocytes. Despite the small number of specimens, this study demonstrates for the first time
a quantitative analysis of endothelial junction proteins in human CCM.
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Cerebral cavernous malformations constitute 5%–10% of all cerebrovascular malformations with a prevalence of approximately 0.5%. The condi-
tion affects cerebral blood vessels, resulting in dilation as 
well as thinning of the vessel wall.1,17 Depending on the 
location of the affected vessel, this often leads to bleed-
ing, causing seizures, the main clinical sign of CCMs, or 
other neurological deteriorations.4,18 Currently, 2 types of 
CCMs can be distinguished: a familial form, which fol-
lows an autosomal dominant pattern of inheritance, and 
a sporadic form.16 The familial form is caused by loss-of-
function mutations in 3 known genes:6,7,13,20 KRIT1 (also 
known as CCM1), CCM2 (also known as malcalvernin 
or osm14), and PDCD10 (also known as CCM3). How-
ever, in many CCM patients such gene mutations are ab-
sent, which indicates additional pathogenic mechanisms. 
The recent findings of PTEN promotor methylation28 or 
disease-modulating factors such as the HEG transmem-
brane receptor12 and the RhoA GTPase25 support this hy-
pothesis.
In vitro cell studies have suggested that endothelial 
cells play a significant role in CCM13,25 and that contacts 
to neighbor cells, such as neuroglia or neurons, and inter-
endothelial cell contacts may be altered.9,15 Zhao et al.27 
showed an impairment of intercellular barrier function of 
endothelial cells, while Clatterbuck et al.5 detected gaps 
in endothelial tight junction formation in CCM. These au-
thors and others conclude that the absence of intercellular 
barrier components renders vessels more susceptible to 
hemorrhage.11,19,23,26 Looking at the intercellular junctions 
in more detail, occludin, as an integral plasma-membrane 
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protein, is found specifically at tight junctions. This pro-
tein, as well VE-cadherin, is specifically expressed in 
endothelial adherence junctions and plays a critical role 
in endothelial cell contacts.22 Intercellular cohesion and 
organization as well as lining and sealing are important 
features of these protein complexes.22,24 Their alterations 
lead to leaky cell contacts followed by permeability and 
paracellular outflow with oozing of erythrocytes. To 
analyze expression of these intracellular proteins within 
the pathological CCM tissue, we focused on the protein 
expression of occludin, VE-cadherin, and CD31 and the 
quantification of possible alteration of these proteins in 
human CCM tissue compared with control tissue. 
Methods
Patients and Tissue Specimens
Surgery was performed for indications unrelated to 
this research project, and there was no sex, age, or race 
bias in the selection of patients. After ethics review board 
approval (No E-69/2008) and patient informed consent 
were obtained, 13 specimens were obtained from 13 pa-
tients (Table 1) undergoing neurosurgical resection of 
CCMs in accordance with institutional guidelines at the 
University Hospital Zurich. (All specimens were obtained 
by the same surgeon [H.B.].) Specimens of nontumor tis-
sue obtained from patients undergoing tumor resection 
and of tissue obtained from patients undergoing epilepsy 
surgery were used as controls. Control tissue was treated 
in the same manner as CCM tissue. The median age of the 
6 female and 7 male patients was 32 years (range 16–51 
years). After resection, the tissue specimens were trans-
ferred immediately to the laboratory (Fig. 1) and divided 
into sections for protein extraction by snap-freezing in 
liquid nitrogen and for cryosection by embedding in op-
timal cutting temperature medium and frozen over dry 
ice. In addition, parts of the tissue were used for routine 
clinical neuropathological examination to verify that the 
specimens met the criteria for the diagnosis of CCM.
Immunofluorescence Analysis
For immunofluorescence analyses, tissue cryosec-
tions (12-µm thick) were mounted on uncoated slides and 
stored at −80°C. For analysis, slides were blocked with 
0.1 M glycine in PBS for 5 minutes and permeabilized 
in 0.2% Triton X-100/PBS for 10 minutes. After block-
ing with 5% goat serum in 1% BSA/PBS for 30 minutes, 
primary antibodies against CD31 (Clon JC70A, mono-
clonal mouse antihuman antibody, DakoCytomation), 
occludin (polyclonal rabbit anti–human antibody, Invit-
rogen Corp.), and VE-cadherin (polyclonal rabbit anti–
human antibody, Cell Signaling Technology Inc.) were 
added and incubated overnight at 4°C. After 3 washing 
steps with PBS (each for 5 minutes), secondary antibodies 
(Cy3-conjugated goat anti–mouse IgG, bivalent fragment 
antigen binding (F[ab′]2) fragments, as well as Cy5-con-jugated goat anti–rabbit antibodies, both from Jackson 
Immuno Research) were added for 45 minutes. Thereaf-
ter the specimens were washed again 3 times with PBS 
and mounted in Lisbeth medium (0.1 M Tris-HCl (pH 
9.5)/glycerol (3:7) containing 50 mg/ml n-propyl gallate. 
Qualitative analysis was performed by means of conven-
tional fluorescence microscopy (Leica DM 6000B). Im-
age processing was performed on a PC workstation using 
TABLE 1: Summary of patient and lesion characteristics*
Patient Characteristics Lesion Characteristics
Case 
No.
Age 
(yrs), 
Sex Ethnicity
Clinical Pre-
sentation
mRS score 
(adm/30-
day FU)
Radiol 
Findings
Family 
Hx Location Side
Diam-
eter 
(mm)
MRI 
Type†
Multiple 
Lesions
MRI Type, 
Unoperat-
ed Lesions
DVA/ 
Associ-
ated‡
 1 59, F caucasian SH 4/3 RH non temporal left 33.1 I N — Y/Y
 2 16, M caucasian SH 3/1 RH non parietal right 55.1 I N — N
 3 38, M caucasian NH-FND 2/1 NRH non frontal left 12.1 II N — N
 4 35, M caucasian SH 3/2 RH non parietal left 24.2 I Y III Y/Y
 5 25, F caucasian NH-FND 0/0 NRH non frontal right 22.4 II Y III, IV N
 6 32, F caucasian NH-FND 1/0 NRH non thalamic right 15.8 II N — N
 7 23, F caucasian SH 5/5 RH 1 SR brachium pontis right 36.7 I Y III, III N
 8 39, F caucasian SH 1/1 RH non brachium pontis left 26.8 I N — N
 9 30, M caucasian SH 4/3 RH non cerebellar right 34.1 I Y III Y/Y
10 50, M caucasian NH-FND 3/3 NRH 1 SR brachium pontis right 19.9 II Y III, IV N
11 51, F caucasian NH-FND 2/1 NRH non brachium pontis left 15.1 II Y III Y/Y
12 19, M caucasian NH-FND 1/1 NRH non brachium pontis right 12.1 II N — Y/Y
13 20, M African NH-FND 1/1 NRH non brachium pontis left 11.6 III N — N
*  Adm = admission; FU = follow-up; N = no; NH-FND = nonhemorrhagic focal neurological deficit; mRS = modified Rankin Scale; NRH = no recent 
hemorrhage; Radiol = Radiological; RH = recent hemorrhage; SH = symptomatic hemorrhage; SR = symptomatic relative; Y = yes. 
†  The MRI type classification was used as previously described.2,4
‡ The letters before the virgule indicate whether or not a DVA was present; the letters after the virgule indicated whether a DVA was directly associated 
with the surgically treated CCM lesion.
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PhotoShop (Adobe Systems) and Image J 1.42q, and im-
ages were processed uniformly.
Polyacrylamide Gel Electrophoresis and Immunoblotting 
The CCM and control samples were homogenized by 
slam freezing, resuspended in SDS sample buffer (3.7 M 
urea, 134.6 mM Tris–HCl, pH 6.8, 5.4% SDS, 2.3% NP-
40, 4.45% β-mercaptoethanol, 4% glycerol, and 6 mg/100 
ml of bromophenol blue) followed by boiling for 1 min-
ute. Samples were run on 8% polyacrylamide gels togeth-
er with All Blue (Bio-Rad Laboratories, Inc.) molecular 
weight marker. Equal amounts of protein were loaded 
for the different tissue extracts as judged by Coomassie 
blue staining from the previous gel. Blotting was carried 
out overnight onto nitrocellulose Amersham Hybond-C 
Extra (GE Healthcare). The same primary antibodies as 
those used for immunofluorescence (against CD31, occlu-
din, and VE-cadherin) and an antibody against all actin 
isoforms (polyclonal rabbit anti–human antibody [Sigma-
Aldrich]) were used for protein loading control. These 
primary antibodies, as well as horseradish peroxidase-
conjugated anti–rabbit Igs (Calbiochem), which were used 
as secondary antibodies, were diluted in low-salt buffer 
supplemented with 4% nonfat milk powder. Antibody in-
cubation was set for 1 hour and was followed by repeated 
washing with low-salt buffer. Chemiluminescence reac-
tion was performed with SuperSignal (Pierce) and visual-
ized on Fuji Medical x-ray films (Fujifilm).
Statistical Analysis
Statistical data analysis was performed with Micro-
soft Excel and SPSS Statistics software. To assess wheth-
er 2 independent samples of observations came from the 
same distribution, a nonparametric test was used (Wil-
coxon–Mann-Whitney test). Probability values less than 
0.05 were considered significant.
Results
Occludin, VE-Cadherin, and CD31
Occludin, VE-cadherin, and CD31 were detected in 
all human cryosection specimens, with a preferred lo-
calization in the intima of the vascular structures. In the 
controls, these proteins were almost exclusively present 
in the small vessels and capillaries and were undetectable 
in the surrounding brain tissue (Figs. 2 and 3), whereas 
immunofluorescent analyses revealed expression of oc-
cludin, VE-cadherin, and CD31 beyond the vascular in-
tima in the CCM specimens. The localization of these 
proteins was mainly detected in small vessels including 
the capillary beds in a dispersed pattern. In some parts 
of the CCM tissue samples, occludin and/or VE-cadherin 
were arranged in clusters with a high concentration, in 
other parts primarily CD31 was present. Furthermore, in 
addition to the intima of the vessels, the surrounding tis-
sue layers next to these clusters also stained positive for 
these proteins. 
Cell-Contact Protein Levels
Expression analysis of the proteins of interest was 
performed by means of Western blot, and all 3 proteins 
could be analyzed by triplicate measurements in all CCM 
and control samples (Fig. 4). Statistical analysis revealed 
a significantly higher expression of CD31 (p = 0.001), oc-
cludin (p = 0.044), and VE-cadherin (p = 0.028) in the 
CCM samples than in the control counterparts. The range 
of expression varied within the individual CCM samples 
(Fig. 4). Analyzing clinicopathological correlations, no 
significant results regarding the localization of the CCM 
lesion (supratentorial vs infratentorial, p = 0.25–0.56), as-
sociated DVA (p = 0.086–0.31) or number of CCM lesions 
(1 vs > 1, p = 0.39–0.56) could be obtained. Comparing 
the active lesions with inactive CCM lesions showed dif-
ferences (although not statistically significant) in the mea-
sured protein levels (Fig. 4). Active state was defined ac-
cording to Al-Shahi Salman et al.2 as a CCM lesion with 
an associated acute hemorrhage before surgery, detected 
by MR imaging/CT scan and confirmed during surgery 
and by pathological examination. The analyses in active 
CCM lesions revealed enhanced levels of CD31 and oc-
cludin and decreased levels of VE-cadherin compared 
with the inactive counterparts.
Discussion
Endothelial cells are thought to be the governing cell 
type involved in CCM, but little is known about intra- and 
intercellular pathogenetic mechanisms, especially in hu-
mans.25,27 Although CCM patients are more likely symp-
tomatic in lesions associated with acute hemorrhagic 
complications, detailed large human clinicopathological 
as well as experimental studies regarding these underly-
ing molecular mechanisms of the disease are currently 
Fig. 1. Macroscopic view of a CCM lesion after resection.
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missing. Interestingly, it seems that CCM-associated 
bleeding is a multifactorial event at the capillary level 
caused by alteration of endothelial cell or blood-brain 
barrier components leading to leakage of red blood cells 
through these lesions into the surrounding brain tissue.13 
In vitro studies of endothelial CCM cells showed that mu-
tations of the known CCM genes induce dysfunction of 
endothelial cells by changes in the cascade of intracellular 
tubular proteins.10,20 While the exact cascades of involved 
intracellular factors and proteins are not completely un-
derstood,12,25 involvement of intercellular proteins, such 
as VE-cadherin, has been recently implicated in this pro-
cess.10,13 Indeed, a growing body of evidence supports the 
notion of the alteration of intercellular junctions between 
neurons, glia, pericytes, and endothelial cells.5,11,19,23,27
In this study, we quantified for the first time in human 
CCM tissue the transmembrane cell-contact proteins oc-
cludin and VE-cadherin (representing main proteins in 
tight and adherence junctions) and the vascular adhesion 
molecule CD31. We found a significant overexpression of 
these proteins in CCM tissue compared with control tis-
sue, with slight variations within the patient samples (Fig. 
4). These differences suggest that patient-specific or other 
unknown factors may influence the expression rate. The 
molecular CCM protein complex model of Hilder et al.,10 
which interacts closely with cytoskeletal proteins and 
modulates interendothelial cell junctions, may explain 
these changes in protein regulation.
Based on these individual protein profiles, protein 
expression levels in the specimens obtained from CCM 
patients were associated to the corresponding clinical 
phenotype to provide further details within the different 
patient subgroups. Although patients with infratentorial 
CCMs are more likely to have neurological symptoms than 
those with supratentorial CCM, we did not find any cor-
relation between differences in protein levels in CCM tis-
sue and CCM location. The distinctive clinical symptoms 
found in association with infratentorial CCMs are rather 
related to the limitation of the infratentorial space and the 
presence of important and sensitive neuronal tracts and 
centers within the brainstem, representing a challenge for 
neurosurgical treatment of these lesions.3,8,21
Fig. 2. Immunostaining of CCM (A–F) and control tissue (G–I) for occludin. A: Overlay of occludin (green), DAPI (red), and 
phalloidin (blue). B: Single-channel image, DAPI. C: Single-channel image, occludin. D: Negative control without primary 
antibodies; overlay of occludin (green), DAPI (red), and phalloidin (blue). E: Single-channel image, DAPI. F: Single-channel 
image, occludin. G: Control tissue, overlay of occludin (green), DAPI (red), and phalloidin (blue). H: Single-channel image, 
DAPI. I: Single-channel image, occludin. Arrows indicate localization of occludin in the inner layer of the vessel. 
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The differences in the protein levels in CCM lesions 
found by Western blot analysis with respect to the pres-
ence of acute associated hemorrhages were highly inter-
esting, although they did not reach statistical significance. 
However, a precise reason for the higher mean rates 
of CD31 and occludin and the lower mean rate of VE-
cadherin in active CCM lesions remains unclear. These 
findings therefore need to be further explored in stud-
ies involving larger patient groups. This also applies to 
CCM-associated DVAs and the number of CCM lesions 
in single patients, since in this study no significant results 
were found regarding the relationship between the levels 
of the proteins of interest and DVAs (their presence or ab-
sence) or number of CCMs (multiple or single locations). 
The immunofluorescence analyses of the CCM tis-
sues showed staining for VE-cadherin, occludin, and 
CD31 in the intima and the surrounding brain tissue. In 
some specimens an arrangement in clusters was found; 
these clusters seem to originate in the intima and expand 
to the surrounding brain tissue. However, the vessels in 
the controls specimens were only slightly stained and did 
not show any cluster arrangements or spread to the sur-
Fig. 3. Immunostaining of CCM (A–G) and control tissue (H) for CD31 and VE-cadherin. A: Overlay of CD31 (green), DAPI 
(red), and phalloidin (blue). B: Single-channel image, DAPI. C: Single-channel image, CD31. D: VE-cadherin (green), DAPI 
(red), and phalloidin (blue). E: Single-channel image, DAPI. F: Single-channel image, VE-cadherin. G: Negative control 
without primary antibodies, overlay of CD31 (green), VE-cadherin (blue), and DAPI (red). H: Control tissue, overlay of CD31 
(green), VE-cadherin (blue), and DAPI (red). Arrows indicate localization of CD31 and VE-cadherin in the inner layer of the 
vessel.
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rounding brain tissue. These immunohistochemical find-
ings confirm the results of the increased protein levels 
revealed by Western blot and are suggestive of compensa-
tory production due to nonfunctional cell contacts.
The weakness of this study can be found in the sam-
ple size, which may lead to an underpowered value of the 
clinicopathological correlation. However, this study does 
quantitatively identify alterations in endothelial junction 
protein expression in human CCMs for the first time. Fu-
ture studies will be designed to pursue functional assays 
in vitro using tissue samples from a larger number of pa-
tients.
Conclusions
Based on the presented results we conclude that 1) the 
abnormal and discontinuous pattern in the investigated 
endothelial cell-contact proteins compared with control 
tissue explains the CCM-associated bleeding or oozing of 
erythrocytes; 2) endothelial cells appear to compensate 
for the loose cell contacts in the pathological situation by 
production of new proteins to strengthen their contacts; 
3) the alterations of VE-cadherin, occludin, and CD31 in 
these CCM patients are not locally based or associated 
with multiplicity of lesions or the presence of DVAs. A 
difference in the expression level of the proteins of in-
terest in the CCM lesions associated with acute hemor-
rhage compared with lesions without recent hemorrhage 
might be possible, but needs to be validated by means of 
functional assays and studies involving a larger number 
of patients.
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